Code Ocean, the leading computational research environment for sharing scientific discoveries, today announced a collaboration that will power AI-driven computational research for oncology-focused drug discovery with Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development. By leveraging Code Ocean's Compute Capsule technology, the move will further power Lantern Pharma's RADR platform for faster, more collaborative discoveries from billions of RADR data points as well as from experimental results and insights from their network of collaborators. Computational researchers today are challenged with analysing big data with too many tools, lack of specialized coding experience, and challenging, cumbersome DevOps processes required to organize and securely share research. Through this collaboration Lantern Pharma is expected to benefit from significant efficiencies in development time and cost as well as increased reproducibility from Code Ocean's platform. The Code Ocean platform will offer an easy to use, collaborative research experience with an integrated development environment, secure repository, and portable Compute Capsule technology for guaranteed reproducibility.

The event's single objective was to accelerate healthcare's pragmatic adoption of new technologies by informing, inspiring, and debating, the role and value of technology innovation to health systems, healthcare workforce, and patients around the world. Click here to find unedited audio, presentations where available, sponsor page, and photos, with links to speaker photos, and the 2nd Annual Innovation Ignition Competition. Partners in Digital Health, publisher of Telehealth and Medicine Today (TMT) has announced a partnership with Orvium, the first decentralized social platform for scientific collaboration, funding, and publications management based on blockchain and artificial Intelligence. TMT will be the first journal to run on the new Orvium decentralized platform. Manuel Martin, CEO and Co-founder of Orvium, said, "This represents another significant milestone for our platform as we move into this next exciting phase of development. Having a major journal like'Telehealth and Medicine Today' as the first to go through our decentralized platform is a strong vote of confidence from a major publisher, and underlines the credentials of our platform."